PharmaForceIQ, an end-to-end, real-time customer engagement platform for the pharmaceutical industry, has announced the acquisition of Aktana, integrating its digital commercialization platform with Aktana’s artificial intelligence-driven field next-best-action (NBA) technology.

The acquisition brings together two complementary platforms to create what the companies describe as the industry’s first “optichannel-in-a-box” solution—an end-to-end commercial engagement system that can be deployed within six to eight weeks. The unified platform is designed to align brand and field strategy, improve execution, and enable immediate measurement of commercial impact.

PharmaForceIQ’s modular, machine learning-powered platform will be integrated with Aktana’s AI core to support long-term scalability and continued innovation across the combined solution. The platform is intended to deliver a single, holistic system for orchestrating personalized customer engagement across both field and digital channels.

The transaction significantly expands PharmaForceIQ’s presence in the United States and strengthens its reach across LATAM, APAC, and EMEA markets. It also enhances the company’s field engagement capabilities by adding deeper predictive insights to help sales teams optimize their interactions with healthcare professionals.

Aktana’s field next-best-action platform is powered by its proprietary Knowledge Nexus dataset, which draws on real-world insights from more than 100 million field recommendations and over 5,000 tactics executed across 85-plus validated use cases over twelve years. According to the company, the platform has demonstrated measurable outcomes, including a 36 per cent lift in new brand prescriptions, a 19 per cent increase in sales performance following competitor launches, and time savings of around 20 minutes per day per sales representative through reduced manual planning.

Hemal Somaiya, Chief Executive and Strategy Officer of PharmaForceIQ, said the acquisition deepens the company’s orchestration capabilities and positions it as the only end-to-end go-to-market engagement platform in the sector. He added that the combined offering will allow PharmaForceIQ to scale faster across global clients while making field teams more effective and improving marketing performance.

Applying optichannel engagement strategies across both field and digital channels has been shown to deliver significant efficiency gains, including a threefold average script lift, a 22 per cent improvement in brand strategy adherence, an 80 per cent increase in healthcare professional engagement, and 20–30 per cent savings in commercial budgets compared with traditional media models.

Derek Choy, Head of Product at PharmaForceIQ and former co-founder and Chief Product Officer of Aktana, said the integration will enable best-in-class orchestration across field and digital channels. He noted that the unified platform will allow teams to better understand customer needs and predict, orchestrate, and measure personalized engagement journeys across field, digital, and peer-to-peer channels.

Over the past two years, Aktana has enhanced its platform with AI-driven communications planning, automated tactic optimization, and real-time strategic visibility to improve healthcare professional journey design and execution. These capabilities will now be supported by PharmaForceIQ’s high-touch partnership model, which the company says has delivered 100 per cent client renewals.

PharmaForceIQ positions itself as a real-time engagement platform that unifies brand and field operations, enabling pharmaceutical companies to predict and orchestrate personalized customer journeys across channels, with clear metrics to demonstrate impact quickly.

Aktana’s optichannel approach focuses on engaging healthcare professionals and patients through the channels that matter most, guided by real-world signals of need, to deliver more relevant and effective interactions.